Form D · Biotechnology
Monte Rosa Therapeutics, Inc.
Boston, MA · CIK 0001826457
Offering snapshot reported Mar 24, 2021 · SEC filing
- Reported sold
- $95M Offering amount: $95M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 11, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 24, 2021 | Initial | $94,999,984 | No comparison | 23 | SEC filing |
| Sep 29, 2020 | Initial | $48,000,000 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-393266
Source: Form D, filed Mar 24, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ali Behbahani | Director |
| Kim Blackwell | Director |
| Bradley Bolzon | Director |
| Chandra P. Leo | Director |
| Alexander Mayweg | Director |
| Drew Schiff | Director |
| Christine Siu | Director |
| Ajim Tamboli | Executive |
| Markus Warmuth | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
40 Guest Street
Boston, MA, 02458
Boston, MA, 02458